A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

This is a randomized, open-label, 2- treatment, 2- period study with a duration of approximately 6 weeks. The Study will comprise of: * A Screening period of 28 days, * Treatment Period 1 on Day 1 and Treatment Period 2 on Day 9 * A Follow-up visit within 7 days (± 2 days) after the last dose in Period 2. Participants will be randomized 1:1 to either Sequence 1 or Sequence 2. * Sequence 1: Treatment A (AZD8630 Monodose inhalation powder) crossover to Treatment B (AZD8630 test inhalation powder). * Sequence 2: Treatment B (AZD8630 test inhalation powder) crossover to Treatment A (AZD8630 Monodose inhalation powder).